Genelux

Update in progress

GNLX (NasdaqCM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Genelux Corporation is a clinical-stage biopharmaceutical company developing oncolytic viral immunotherapies for aggressive solid tumors. Its lead candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a modified vaccinia virus aimed at treating ovarian cancer. The company also offers the CHOICE platform and a library of engineered oncolytic VACV candidates. It has a license with Newsoara BioPharma to develop Olvi-Vec in China. Founded in 2001, based in Westlake Village, California.

Company score

Sentiment: 0.27; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.39; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.13; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.14; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.21; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive